The DOI matches its Crossref record; 260 of the 260 references it cites were found in a registry or an index.
Emerging Concepts and Technologies in Vaccine Development
Open accessAbstract
Despite the success of vaccination to greatly mitigate or eliminate threat of diseases caused by pathogens, there are still known diseases and emerging pathogens for which the development of successful vaccines against them is inherently difficult. In addition, vaccine development for people with compromised immunity and other pre-existing medical conditions has remained a major challenge. Besides the traditional inactivated or live attenuated, virus-vectored and subunit vaccines, emerging non-viral vaccine technologies, such as viral-like particle and nanoparticle vaccines, DNA/RNA vaccines, and rational vaccine design, offer innovative approaches to address existing challenges of vaccine development. They have also significantly advanced our understanding of vaccine immunology and can guide future vaccine development for many diseases, including rapidly emerging infectious diseases, such as COVID-19, and diseases that have not traditionally been addressed by vaccination, such as cancers and substance abuse. This review provides an integrative discussion of new non-viral vaccine development technologies and their use to address the most fundamental and ongoing challenges of vaccine development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pushko, P., Pumpens, P., & Grens, E. (2013) · Intervirology · doi:10.1159/000346773 · Cited by 5,950
mRNA vaccines — a new era in vaccinology
Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.243 · Cited by 4,667 · cited 3×
“RNA vaccines have been used in a number of studies in animal models (68) and have recently completed phase 1 clinical trials for rabies (57, 69) and influenza (68, 70).”
BackgroundChimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Folegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419
Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy
Kranz, L. M., Diken, M., Haas, H., Kreiter, S., Loquai, C., Reuter, K. C., Meng, M., Fritz, D., Vascotto, F., Hefesha, H., et al. (2016) · Nature · doi:10.1038/nature18300 · Cited by 1,819
Coutinho, A. E., & Chapman, K. E. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2010.04.005 · Cited by 1,815
Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1
Wu, X., Yang, Z.-Y., Li, Y., Hogerkorp, C.-M., Schief, W. R., Seaman, M. S., Zhou, T., Schmidt, S. D., Wu, L., Xu, L., et al. (2010) · Science · doi:10.1126/science.1187659 · Cited by 1,730
Mulligan, M. J., Lyke, K. E., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Raabe, V., Bailey, R., Swanson, K. A., et al. (2020) · doi:10.1101/2020.06.30.20142570 · Cited by 1,569
Developing Covid-19 Vaccines at Pandemic Speed
Lurie, N., Saville, M., Hatchett, R., & Halton, J. (2020) · New England Journal of Medicine · doi:10.1056/nejmp2005630 · Cited by 1,557
Zhu, F.-C., Li, Y.-H., Guan, X.-H., Hou, L.-H., Wang, W.-J., Li, J.-X., Wu, S.-P., Wang, B.-S., Wang, Z., Wang, L., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31208-3 · Cited by 1,382
Zhu, F.-C., Guan, X.-H., Li, Y.-H., Huang, J.-Y., Jiang, T., Hou, L.-H., Li, J.-X., Yang, B.-F., Wang, L., Wang, W.-J., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31605-6 · Cited by 1,225
Personalized vaccines for cancer immunotherapy
Sahin, U., & Türeci, Ö. (2018) · Science · doi:10.1126/science.aar7112 · Cited by 1,147
Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus
McLellan, J. S., Chen, M., Joyce, M. G., Sastry, M., Stewart-Jones, G. B. E., Yang, Y., Zhang, B., Chen, L., Srivatsan, S., Zheng, A., et al. (2013) · Science · doi:10.1126/science.1243283 · Cited by 1,126
SARS-CoV-2 Vaccines: Status Report
Amanat, F., & Krammer, F. (2020) · Immunity · doi:10.1016/j.immuni.2020.03.007 · Cited by 1,120
Hu, S., Marshall, C., Darby, J., Wei, W., Lyons, A. B., & Körner, H. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00001 · Cited by 973
Bharathavikru, S., & Dudnakova, T. (2016) · Cited by 957
Factors That Influence the Immune Response to Vaccination
Zimmermann, P., & Curtis, N. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00084-18 · Cited by 939
Zhao, L., Seth, A., Wibowo, N., Zhao, C.-X., Mitter, N., Yu, C., & Middelberg, A. P. J. (2014) · Vaccine · doi:10.1016/j.vaccine.2013.11.069 · Cited by 919
ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques
van Doremalen, N., Lambe, T., Spencer, A., Belij-Rammerstorfer, S., Purushotham, J. N., Port, J. R., Avanzato, V. A., Bushmaker, T., Flaxman, A., Ulaszewska, M., et al. (2020) · Nature · doi:10.1038/s41586-020-2608-y · Cited by 914
The origins of age-related proinflammatory state
Ferrucci, L., Corsi, A., Lauretani, F., Bandinelli, S., Bartali, B., Taub, D. D., Guralnik, J. M., & Longo, D. L. (2005) · Blood · doi:10.1182/blood-2004-07-2599 · Cited by 908
First Results of Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Children
The RTS, S. C. T. P. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102287 · Cited by 896
Single-Shot Ad26 Vaccine Protects Against SARS-CoV-2 in Rhesus Macaques
Mercado, N. B., Zahn, R., Wegmann, F., Loos, C., Chandrashekar, A., Yu, J., Liu, J., Peter, L., McMahan, K., Tostanoski, L. H., et al. (2020) · Nature · doi:10.1038/s41586-020-2607-z · Cited by 789
Didierlaurent, A. M., Morel, S., Lockman, L., Giannini, S. L., Bisteau, M., Carlsen, H., Kielland, A., Vosters, O., Vanderheyde, N., Schiavetti, F., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901474 · Cited by 758
A Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Infants
The RTS, S. C. T. P. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1208394 · Cited by 752
Lipid Nanoparticle Assisted mRNA Delivery for Potent Cancer Immunotherapy
Oberli, M. A., Reichmuth, A. M., Dorkin, J. R., Mitchell, M. J., Fenton, O. S., Jaklenec, A., Anderson, D. G., Langer, R., & Blankschtein, D. (2017) · Nano Letters · doi:10.1021/acs.nanolett.6b03329 · Cited by 719
Aiello, A., Farzaneh, F., Candore, G., Caruso, C., Davinelli, S., Gambino, C. M., Ligotti, M. E., Zareian, N., & Accardi, G. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02247 · Cited by 693
Advances in mRNA Vaccines for Infectious Diseases
Zhang, C., Maruggi, G., Shan, H., & Li, J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00594 · Cited by 665
Nozaradan, S., Peretz, I., & Keller, P. E. (2016) · Scientific Reports · doi:10.1038/srep20612 · Cited by 662
Vaccine Adjuvants: from 1920 to 2015 and Beyond
Pasquale, A., Preiss, S., Silva, F., & Garçon, N. (2015) · Vaccines · doi:10.3390/vaccines3020320 · Cited by 648
Plotkin, S. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1400472111 · Cited by 642 · cited 1×
“A disadvantage of subunit vaccines is that they are generally less immunogenic in nature and therefore require adjuvants and repeated vaccination doses (2).”
BackgroundBahl, K., Senn, J. J., Yuzhakov, O., Bulychev, A., Brito, L. A., Hassett, K. J., Laska, M. E., Smith, M., Almarsson, Ö., Thompson, J., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.035 · Cited by 642 · cited 1×
“RNA vaccines have been used in a number of studies in animal models (68) and have recently completed phase 1 clinical trials for rabies (57, 69) and influenza (68, 70).”
BackgroundKushnir, N., Streatfield, S. J., & Yusibov, V. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.10.083 · Cited by 587
Virus-like particles: Passport to immune recognition
Grgacic, E. V. L., & Anderson, D. A. (2006) · Methods · doi:10.1016/j.ymeth.2006.07.018 · Cited by 582
New Vaccine Technologies to Combat Outbreak Situations
Rauch, S., Jasny, E., Schmidt, K. E., & Petsch, B. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01963 · Cited by 579
Innate Immune Function by Toll-like Receptors: Distinct Responses in Newborns and the Elderly
Kollmann, T. R., Levy, O., Montgomery, R. R., & Goriely, S. (2012) · Immunity · doi:10.1016/j.immuni.2012.10.014 · Cited by 565
Major findings and recent advances in virus–like particle (VLP)-based vaccines
Mohsen, M. O., Zha, L., Cabral-Miranda, G., & Bachmann, M. F. (2017) · Seminars in Immunology · doi:10.1016/j.smim.2017.08.014 · Cited by 555
Butts, C., Socinski, M. A., Mitchell, P. L., Thatcher, N., Havel, L., Krzakowski, M., Nawrocki, S., Ciuleanu, T.-E., Bosquée, L., Trigo, J. M., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70510-2 · Cited by 538
Alberer, M., Gnad-Vogt, U., Hong, H. S., Mehr, K. T., Backert, L., Finak, G., Gottardo, R., Bica, M. A., Garofano, A., Koch, S. D., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31665-3 · Cited by 530
Nanoparticle Vaccines Against Infectious Diseases
Pati, R., Shevtsov, M., & Sonawane, A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02224 · Cited by 514
The SARS-CoV-2 Vaccine Pipeline: an Overview
Chen, W.-H., Strych, U., Hotez, P. J., & Bottazzi, M. E. (2020) · Current Tropical Medicine Reports · doi:10.1007/s40475-020-00201-6 · Cited by 511
The potential danger of suboptimal antibody responses in COVID-19
Iwasaki, A., & Yang, Y. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0321-6 · Cited by 509
Engineering dendritic cell vaccines to improve cancer immunotherapy
Perez, C. R., & De Palma, M. (2019) · Nature Communications · doi:10.1038/s41467-019-13368-y · Cited by 505
Vogel, A. B., Lambert, L., Kinnear, E., Busse, D., Erbar, S., Reuter, K. C., Wicke, L., Perkovic, M., Beissert, T., Haas, H., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2017.11.017 · Cited by 501
Inflamm‐ageing and lifelong antigenic load as major determinants of ageing rate and longevity
De Martinis, M., Franceschi, C., Monti, D., & Ginaldi, L. (2005) · FEBS Letters · doi:10.1016/j.febslet.2005.02.055 · Cited by 492
Early Transcription and Silencing of Cytokine Genes Underlie Polarization of T Helper Cell Subsets
Grogan, J. L., Mohrs, M., Harmon, B., Lacy, D. A., Sedat, J. W., & Locksley, R. M. (2001) · Immunity · doi:10.1016/s1074-7613(01)00103-0 · Cited by 485
In situ vaccination with cowpea mosaic virus nanoparticles suppresses metastatic cancer
Lizotte, P. H., Wen, A. M., Sheen, M. R., Fields, J., Rojanasopondist, P., Steinmetz, N. F., & Fiering, S. (2016) · Nature Nanotechnology · doi:10.1038/nnano.2015.292 · Cited by 485
GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives
Garçon, N., Chomez, P., & Van Mechelen, M. (2007) · Expert Review of Vaccines · doi:10.1586/14760584.6.5.723 · Cited by 476
Morel, S., Didierlaurent, A., Bourguignon, P., Delhaye, S., Baras, B., Jacob, V., Planty, C., Elouahabi, A., Harvengt, P., & Carlsen, H. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.01.011 · Cited by 476
DNA Vaccines—How Far From Clinical Use?
Hobernik, D., & Bros, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113605 · Cited by 457
Use of defined TLR ligands as adjuvants within human vaccines
Duthie, M. S., Windish, H. P., Fox, C. B., & Reed, S. G. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00978.x · Cited by 437
Fundamentals of vaccine immunology
Clem, A. (2011) · Journal of Global Infectious Diseases · doi:10.4103/0974-777x.77299 · Cited by 435
Reverse vaccinology 2.0: Human immunology instructs vaccine antigen design
Rappuoli, R., Bottomley, M. J., D’Oro, U., Finco, O., & De Gregorio, E. (2016) · Journal of Experimental Medicine · doi:10.1084/jem.20151960 · Cited by 435
Schuster, J., Lai, R. K., Recht, L. D., Reardon, D. A., Paleologos, N. A., Groves, M. D., Mrugala, M. M., Jensen, R., Baehring, J. M., Sloan, A., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nou348 · Cited by 422
Infectious vaccinia virus recombinants that express hepatitis B virus surface antigen
Smith, G. L., Mackett, M., & Moss, B. (1983) · Nature · doi:10.1038/302490a0 · Cited by 420
Efficacy of RTS,S/AS01E Vaccine against Malaria in Children 5 to 17 Months of Age
Bejon, P., Lusingu, J., Olotu, A., Leach, A., Lievens, M., Vekemans, J., Mshamu, S., Lang, T., Gould, J., Dubois, M.-C., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807381 · Cited by 417
Cancer DNA vaccines: current preclinical and clinical developments and future perspectives
Lopes, A., Vandermeulen, G., & Préat, V. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1154-7 · Cited by 385
Beyond antigens and adjuvants: formulating future vaccines
Moyer, T. J., Zmolek, A. C., & Irvine, D. J. (2016) · Journal of Clinical Investigation · doi:10.1172/jci81083 · Cited by 374
Viruses as vaccine vectors for infectious diseases and cancer
Draper, S. J., & Heeney, J. L. (2010) · Nature Reviews Microbiology · doi:10.1038/nrmicro2240 · Cited by 353
Wertheimer, A. M., Bennett, M. S., Park, B., Uhrlaub, J. L., Martinez, C., Pulko, V., Currier, N. L., Nikolich-Žugich, D., Kaye, J., & Nikolich-Žugich, J. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1301721 · Cited by 352
Polymer-Based Nanomaterials and Applications for Vaccines and Drugs
Han, J., Zhao, D., Li, D., Wang, X., Jin, Z., & Zhao, K. (2018) · Polymers · doi:10.3390/polym10010031 · Cited by 327
Wang, Z., Troilo, P. J., Wang, X., Griffiths, T. G., Pacchione, S. J., Barnum, A. B., Harper, L. B., Pauley, C. J., Niu, Z., Denisova, L., et al. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302213 · Cited by 322
Virus-like particles: flexible platforms for vaccine development
Chackerian, B. (2007) · Expert Review of Vaccines · doi:10.1586/14760584.6.3.381 · Cited by 321
Wilgenhof, S., Corthals, J., Heirman, C., van Baren, N., Lucas, S., Kvistborg, P., Thielemans, K., & Neyns, B. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.4121 · Cited by 313
Association between nasal shedding and fever that influenza A (H3N2) induces in dogs
Song, D., Moon, H., Jung, K., Yeom, M., Kim, H. K., Han, S. Y., An, D.-J., Oh, J.-S., Kim, J.-M., Park, B., et al. (2011) · Virology Journal · doi:10.1186/1743-422x-8-1 · Cited by 303
Nanoparticle-Based Vaccines Against Respiratory Viruses
Al-Halifa, S., Gauthier, L., Arpin, D., Bourgault, S., & Archambault, D. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00022 · Cited by 299
Ensuring global access to COVID-19 vaccines
Yamey, G., Schäferhoff, M., Hatchett, R., Pate, M., Zhao, F., & McDade, K. K. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30763-7 · Cited by 298
Elimination of large tumors in mice by mRNA-encoded bispecific antibodies
Stadler, C. R., Bähr-Mahmud, H., Celik, L., Hebich, B., Roth, A. S., Roth, R. P., Karikó, K., Türeci, Ö., & Sahin, U. (2017) · Nature Medicine · doi:10.1038/nm.4356 · Cited by 290
Kübler, H., Scheel, B., Gnad-Vogt, U., Miller, K., Schultze-Seemann, W., vom Dorp, F., Parmiani, G., Hampel, C., Wedel, S., Trojan, L., et al. (2015) · Journal for Immunotherapy of Cancer · doi:10.1186/s40425-015-0068-y · Cited by 287
Agger, E. M., Rosenkrands, I., Hansen, J., Brahimi, K., Vandahl, B. S., Aagaard, C., Werninghaus, K., Kirschning, C., Lang, R., Christensen, D., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003116 · Cited by 287
Going beyond the liver: progress and challenges of targeted delivery of siRNA therapeutics
Lorenzer, C., Dirin, M., Winkler, A.-M., Baumann, V., & Winkler, J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.02.003 · Cited by 284
Vallin, H., Perers, A., ALM, G. V., & Rönnblom, L. (1999) · PubMed · Cited by 284
Changes in primary lymphoid organs with aging
Chinn, I. K., Blackburn, C. C., Manley, N. R., & Sempowski, G. D. (2012) · Seminars in Immunology · doi:10.1016/j.smim.2012.04.005 · Cited by 282
A vaccine against nicotine for smoking cessation: a randomized controlled trial
Cornuz, J., Zwahlen, S., Jungi, W. F., Osterwalder, J., Klingler, K., van Melle, G., Bangala, Y., Guessous, I., Müller, P., Willers, J., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002547 · Cited by 281
Live recombinant vaccinia virus protects chimpanzees against hepatitis B
Moss, B., Smith, G. L., Gerin, J. L., & Purcell, R. H. (1984) · Nature · doi:10.1038/311067a0 · Cited by 281
Unique aspects of the perinatal immune system
Zhang, X., Zhivaki, D., & Lo-Man, R. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.54 · Cited by 276
Rosalia, R. A., Cruz, L. J., van Duikeren, S., Tromp, A. T., Silva, A. L., Jiskoot, W., de Gruijl, T., Löwik, C., Oostendorp, J., van der Burg, S. H., et al. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2014.10.053 · Cited by 269
Martell, B. A., Orson, F. M., Poling, J., Mitchell, E., Rossen, R. D., Gardner, T., & Kosten, T. R. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.128 · Cited by 263
Vallin, H., Perers, A., Alm, G. V., & Rönnblom, L. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.11.6306 · Cited by 256
Vaccine technologies: From whole organisms to rationally designed protein assemblies
Karch, C. P., & Burkhard, P. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.05.001 · Cited by 251
van Dissel, J. T., Joosten, S. A., Hoff, S. T., Soonawala, D., Prins, C., Hokey, D. A., O’Dee, D. M., Graves, A., Thierry-Carstensen, B., Andreasen, L. V., et al. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.10.036 · Cited by 243
Immunologic Basis of Vaccine Vectors
Liu, M. A. (2010) · Immunity · doi:10.1016/j.immuni.2010.10.004 · Cited by 237
Knudsen, N. P. H., Olsen, A., Buonsanti, C., Follmann, F., Zhang, Y., Coler, R. N., Fox, C. B., Meinke, A., D´Oro, U., Casini, D., et al. (2016) · Scientific Reports · doi:10.1038/srep19570 · Cited by 235
Preclinical and clinical development of neoantigen vaccines
Li, L., Goedegebuure, S. P., & Gillanders, W. E. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx681 · Cited by 232
RNA-Based Vaccines in Cancer Immunotherapy
McNamara, M. A., Nair, S. K., & Holl, E. K. (2015) · Journal of Immunology Research · doi:10.1155/2015/794528 · Cited by 221
Suppression of psychoactive effects of cocaine by active immunization
Carrera, M. R. A., Ashley, J. A., Parsons, L. H., Wirsching, P., Koob, G. F., & Janda, K. D. (1995) · Nature · doi:10.1038/378727a0 · Cited by 220
Engineering virus-like particles as vaccine platforms
Frietze, K. M., Peabody, D. S., & Chackerian, B. (2016) · Current Opinion in Virology · doi:10.1016/j.coviro.2016.03.001 · Cited by 217
Vaccine Strategies to Improve Anti-cancer Cellular Immune Responses
Vermaelen, K. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00008 · Cited by 215
DNA vaccines: roles against diseases
Khan, K. H. (2013) · GERMS · doi:10.11599/germs.2013.1034 · Cited by 212
The evolution of human anti-double-stranded DNA autoantibodies
Wellmann, U., Letz, M., Herrmann, M., Angermüller, S., Kalden, J. R., & Winkler, T. H. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500132102 · Cited by 210
Preclinical Evaluation of TriMix and Antigen mRNA-Based Antitumor Therapy
Van Lint, S., Goyvaerts, C., Maenhout, S., Goethals, L., Disy, A., Benteyn, D., Pen, J., Bonehill, A., Heirman, C., Breckpot, K., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2957 · Cited by 210
Vaccine Pharmacotherapy for the Treatment of Cocaine Dependence
Martell, B. A., Mitchell, E., Poling, J., Gonsai, K., & Kosten, T. R. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.04.032 · Cited by 207
Emerging Technologies for Low‐Cost, Rapid Vaccine Manufacture
Kis, Z., Shattock, R., Shah, N., & Kontoravdi, C. (2019) · Biotechnology Journal · doi:10.1002/biot.201800376 · Cited by 207
Wang, Y., Zhang, L., Xu, Z., Miao, L., & Huang, L. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2017.11.009 · Cited by 206
Wilgenhof, S., Van Nuffel, A. M. T., Benteyn, D., Corthals, J., Aerts, C., Heirman, C., Van Riet, I., Bonehill, A., Thielemans, K., & Neyns, B. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt245 · Cited by 203
Post Isolation Modification of Exosomes for Nanomedicine Applications
Hood, J. L. (2016) · Nanomedicine · doi:10.2217/nnm-2016-0102 · Cited by 201
Human therapeutic cocaine vaccine: safety and immunogenicity
Kosten, T. R., Rosen, M., Bond, J., Settles, M., Roberts, J. S. C., Shields, J., Jack, L., & Fox, B. (2002) · Vaccine · doi:10.1016/s0264-410x(01)00425-x · Cited by 193
New hepatitis B vaccine formulated with an improved adjuvant system
Kundi, M. (2007) · Expert Review of Vaccines · doi:10.1586/14760584.6.2.133 · Cited by 193
Diken, M., Kreiter, S., Selmi, A., Britten, C. M., Huber, C., Türeci, Ö., & Sahin, U. (2011) · Gene Therapy · doi:10.1038/gt.2011.17 · Cited by 192
Advances in experimental medicine and biology
(1984) · International Journal of Biochemistry · doi:10.1016/0020-711x(84)90204-0 · Cited by 191
Personalized Dendritic Cell Vaccines‐Recent Breakthroughs and Encouraging Clinical Results
Mastelic-Gavillet, B., Balint, K., Boudousquie, C., Gannon, P. O., & Kandalaft, L. E. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00766 · Cited by 189
In Vivo Characteristics of Cationic Liposomes as Delivery Vectors for Gene Therapy
Audouy, S. A. L., de Leij, L. F. M. H., Hoekstra, D., & Molema, G. (2002) · Pharmaceutical Research · doi:10.1023/a:1020989709019 · Cited by 189
Replication-defective viruses as vaccines and vaccine vectors
Dudek, T., & Knipe, D. M. (2006) · Virology · doi:10.1016/j.virol.2005.09.020 · Cited by 188
Immunogenicity and Smoking-Cessation Outcomes for a Novel Nicotine Immunotherapeutic
Hatsukami, D. K., Jorenby, D. E., Gonzales, D., Rigotti, N. A., Glover, E. D., Oncken, C. A., Tashkin, D. P., Reus, V. I., Akhavain, R. C., Fahim, R. E. F., et al. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.317 · Cited by 186
Rea, D., van Kooten, C., van Meijgaarden, K. E., Ottenhoff, T. H. M., Melief, C. J. M., & Offringa, R. (2000) · Blood · doi:10.1182/blood.v95.10.3162 · Cited by 184
Lu, C., Stewart, D. J., Lee, J. J., Ji, L., Ramesh, R., Jayachandran, G., Nunez, M. I., Wistuba, I. I., Erasmus, J. J., Hicks, M. E., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034833 · Cited by 184
The future of human DNA vaccines
Li, L., Saade, F., & Petrovsky, N. (2012) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2012.08.012 · Cited by 181
mRNA-based dendritic cell vaccines
Benteyn, D., Heirman, C., Bonehill, A., Thielemans, K., & Breckpot, K. (2015) · Expert Review of Vaccines · doi:10.1586/14760584.2014.957684 · Cited by 180
Mason, N. J., Gnanandarajah, J. S., Engiles, J. B., Gray, F., Laughlin, D., Gaurnier-Hausser, A., Wallecha, A., Huebner, M., & Paterson, Y. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0088 · Cited by 178
Efficacy of a Low-Cost, Heat-Stable Oral Rotavirus Vaccine in Niger
Isanaka, S., Guindo, O., Langendorf, C., Matar Seck, A., Plikaytis, B. D., Sayinzoga-Makombe, N., McNeal, M. M., Meyer, N., Adehossi, E., Djibo, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609462 · Cited by 178
Henriksen‐Lacey, M., Christensen, D., Bramwell, V. W., Lindenstrøm, T., Agger, E. M., Andersen, P. L., & Perrie, Y. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.03.027 · Cited by 175
Dimmock, N. J., & Easton, A. J. (2014) · Journal of Virology · doi:10.1128/jvi.03193-13 · Cited by 175
Influenza Virus-Like Particles Containing M2 Induce Broadly Cross Protective Immunity
Song, J.-M., Wang, B.-Z., Park, K.-M., Van Rooijen, N., Quan, F.-S., Kim, M.-C., Jin, H.-T., Pekosz, A., Compans, R. W., & Kang, S.-M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0014538 · Cited by 175
Don’t rush to deploy COVID-19 vaccines and drugs without sufficient safety guarantees
Jiang, S. (2020) · Nature · doi:10.1038/d41586-020-00751-9 · Cited by 174
Protein-based nanoparticles in cancer vaccine development
Neek, M., Kim, T. I., & Wang, S.-W. (2019) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2018.09.004 · Cited by 172
Vaccines: From Empirical Development to Rational Design
Rueckert, C., & Guzmán, C. A. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1003001 · Cited by 171
Antigen-specific vaccines for cancer treatment
Tagliamonte, M., Petrizzo, A., Tornesello, M. L., Buonaguro, L., & Buonaguro, L. (2014) · Human Vaccines & Immunotherapeutics · doi:10.4161/21645515.2014.973317 · Cited by 171
Kline, G. H., Hayden, T. A., & Klinman, N. R. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.6.3342 · Cited by 170
Murata, K., Lechmann, M., Qiao, M., Gunji, T., Alter, H. J., & Liang, T. J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1131929100 · Cited by 170
Olotu, A., Lusingu, J., Leach, A., Lievens, M., Vekemans, J., Msham, S., Lang, T., Gould, J., Dubois, M.-C., Jongert, E., et al. (2011) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70262-0 · Cited by 170
Ageing is associated with diminished apoptotic cell clearance in vivo
Aprahamian, T., Takemura, Y., Goukassian, D., & Walsh, K. (2008) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2008.03658.x · Cited by 167
B cell maintenance and function in aging
Kogut, I., Scholz, J. L., Cancro, M. P., & Cambier, J. C. (2012) · Seminars in Immunology · doi:10.1016/j.smim.2012.04.004 · Cited by 166
Toll-Like Receptor Agonists: Are They Good Adjuvants?
Gnjatic, S., Sawhney, N. B., & Bhardwaj, N. (2010) · The Cancer Journal · doi:10.1097/ppo.0b013e3181eaca65 · Cited by 165
Vaccine for cocaine dependence: A randomized double-blind placebo-controlled efficacy trial
Kosten, T. R., Domingo, C. B., Shorter, D., Orson, F., Green, C., Somoza, E., Sekerka, R., Levin, F. R., Mariani, J. J., Stitzer, M., et al. (2014) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2014.04.003 · Cited by 160
Zika virus-like particle (VLP) based vaccine
Boigard, H., Alimova, A., Martin, G. R., Katz, A., Gottlieb, P., & Galarza, J. M. (2017) · PLOS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0005608 · Cited by 159
Universal influenza vaccines: Shifting to better vaccines
Scorza, F. B., Tsvetnitsky, V., & Donnelly, J. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.03.085 · Cited by 156
Paradoxical changes in innate immunity in aging: recent progress and new directions
Montgomery, R. R., & Shaw, A. C. (2015) · Journal of Leukocyte Biology · doi:10.1189/jlb.5mr0315-104r · Cited by 147
Regulatory T cells and tolerogenic dendritic cells: from basic biology to clinical applications
Rutella, S., & Lemoli, R. M. (2004) · Immunology Letters · doi:10.1016/j.imlet.2004.04.015 · Cited by 147
Deml, L., Speth, C., Dierich, M. P., Wolf, H. J., & Wagner, R. (2004) · Molecular Immunology · doi:10.1016/j.molimm.2004.06.028 · Cited by 147
Leukocyte function in the aging immune system
Desai, A., Grolleau‐Julius, A., & Yung, R. L. (2010) · Journal of Leukocyte Biology · doi:10.1189/jlb.0809542 · Cited by 147
Nanoparticle Systems for Cancer Vaccine
Wen, R. M., Umeano, A. C., Kou, Y., Xu, J., & Farooqı, A. A. (2019) · Nanomedicine · doi:10.2217/nnm-2018-0147 · Cited by 144
Challenges and advances towards the rational design of mRNA vaccines
Pollard, C., Koker, S. D., Saelens, X., Vanham, G. L., & Grooten, J. (2013) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2013.09.002 · Cited by 138
Bremer, P. T., Kimishima, A., Schlosburg, J. E., Zhou, B., Collins, K. C., & Janda, K. D. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201511654 · Cited by 138
Preclinical Mammalian Safety Studies of EPHARNA (DOPC Nanoliposomal EphA2-Targeted siRNA)
Wagner, M. J., Mitra, R., McArthur, M. J., Baze, W. B., Barnhart, K. F., Wu, S. Y., Rodriguez‐Aguayo, C., Zhang, X., Coleman, R. L., Lopez‐Berestein, G., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0541 · Cited by 137
Behzad, H., Huckriede, A. L. W., Haynes, L., Gentleman, B., Coyle, K. M., Wilschut, J., Kollmann, T. R., Reed, S. G., & McElhaney, J. E. (2011) · The Journal of Infectious Diseases · doi:10.1093/infdis/jir769 · Cited by 135
Stephan, R. P., Lill-Elghanian, D. A., & Witte, P. L. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.4.1598 · Cited by 132
The aged lymphoid tissue environment fails to support naïve T cell homeostasis
Becklund, B. R., Purton, J. F., Ramsey, C., Favre, S., Vogt, T. K., Martin, C. E., Spasova, D. S., Sarkisyan, G., LeRoy, E., Tan, J. T., et al. (2016) · Scientific Reports · doi:10.1038/srep30842 · Cited by 131
Gill, M. A., Palucka, K., Barton, T., Ghaffar, F., Jafri, H. S., Banchereau, J., & Ramilo, O. (2005) · The Journal of Infectious Diseases · doi:10.1086/428589 · Cited by 129
Virus-like particle display of HER2 induces potent anti-cancer responses
Palladini, A., Thrane, S., Janitzek, C. M., Pihl, J., Clemmensen, S. B., de Jongh, W. A., Clausen, T. M., Nicoletti, G., Landuzzi, L., Penichet, M. L., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1408749 · Cited by 129
Intranasal mRNA nanoparticle vaccination induces prophylactic and therapeutic anti-tumor immunity
Phua, K. K. L., Staats, H. F., Leong, K. W., & Nair, S. K. (2014) · Scientific Reports · doi:10.1038/srep05128 · Cited by 127
Therapeutic anti‐tumor immunity triggered by injections of immunostimulating single‐stranded RNA
Scheel, B., Aulwurm, S., Probst, J., Stitz, L., Hoerr, I., Rammensee, H., Weller, M., & Pascolo, S. (2006) · European Journal of Immunology · doi:10.1002/eji.200635910 · Cited by 124
Pertussis and influenza immunisation during pregnancy: a landscape review
Raya, B. A., Edwards, K. M., Scheifele, D. W., & Halperin, S. A. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30190-1 · Cited by 122
Paliard, X., Liu, Y., Wagner, R., Wolf, H. J., Baenziger, J., & Walker, C. M. (2000) · AIDS Research and Human Retroviruses · doi:10.1089/088922200309368 · Cited by 121
Cancer vaccines: Enhanced immunogenic modulation through therapeutic combinations
Gatti-Mays, M. E., Redman, J. M., Collins, J. M., & Bilušić, M. (2017) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2017.1364322 · Cited by 119
Oyarzún, P., & Kobe, B. (2015) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1094595 · Cited by 118
Hess, P. R., Boczkowski, D., Nair, S. K., Snyder, D. J., & Gilboa, E. (2005) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-005-0064-z · Cited by 117
Tartaglia, J., Jarrett, O., Neil, J. C., Desmettre, P., & Paoletti, E. (1993) · Journal of Virology · doi:10.1128/jvi.67.4.2370-2375.1993 · Cited by 116
Wiedermann, U., Wiltschke, C., Jasińska, J., Kundi, M., Zurbriggen, R., Garner‐Spitzer, E., Bartsch, R., Steger, G. G., Pehamberger, H., Scheiner, O., et al. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0666-9 · Cited by 116
A Vaccine Strategy that Induces Protective Immunity against Heroin
Stowe, G. N., Vendruscolo, L. F., Edwards, S., Schlosburg, J. E., Misra, K., Schulteis, G., Mayorov, A. V., Zakhari, J. S., Koob, G. F., & Janda, K. D. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200461m · Cited by 116
Turning Tumors into Vaccines: Co-opting the Innate Immune System
van den Boorn, J. G., & Hartmann, G. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.011 · Cited by 116
Chamorro, S., García-Vallejo, J. J., Unger, W. W. J., Fernandes, R. J., Bruijns, S. C. M., Laban, S., Roep, B. O., Hart, B. A. ‘., & van Kooyk, Y. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0801155 · Cited by 116
Chimpanzee Adenovirus Vaccine Provides Multispecies Protection against Rift Valley Fever
Warimwe, G. M., Gesharisha, J., Carr, B. V., Otieno, S., Otingah, K., Wright, D., Charleston, B., Okoth, E., López-Gil, E., Lorenzo, G., et al. (2016) · Scientific Reports · doi:10.1038/srep20617 · Cited by 116
Structural and Computational Biology in the Design of Immunogenic Vaccine Antigens
Liljeroos, L., Malito, E., Ferlenghi, I., & Bottomley, M. J. (2015) · Journal of Immunology Research · doi:10.1155/2015/156241 · Cited by 115
Cho, E.-A., Moloney, F. J., Cai, H., Au-Yeung, A., China, C., Scolyer, R. A., Yosufi, B., Raftery, M. J., Deng, J. Z., Morton, S. W., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)62166-7 · Cited by 114
Shukla, S., Myers, J., Woods, S. E., Gong, X., Czapar, A. E., Commandeur, U., Huang, A. Y.-C., Levine, A. D., & Steinmetz, N. F. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.12.030 · Cited by 112
Martínez‐Sáez, N., Peregrina, J. M., & Corzana, F. (2017) · Chemical Society Reviews · doi:10.1039/c6cs00858e · Cited by 112
Zupančič, E., Curato, C., Paisana, M. C., Rodrigues, C. A. B., Porat, Z., Viana, A. S., Afonso, C. A. M., Pinto, J. F., Gaspar, R. S., Moreira, J. N., et al. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.05.014 · Cited by 110
Peng, B., Wang, L. R., Román, R. G., Davis‐Warren, A., Montefiori, D. C., Kalyanaraman, V. S., Venzon, D. J., Zhao, J., Kan, E., Rowell, T. J., et al. (2005) · Journal of Virology · doi:10.1128/jvi.79.16.10200-10209.2005 · Cited by 107
Innate immunesenescence: underlying mechanisms and clinical relevance
Hazeldine, J., & Lord, J. M. (2015) · Biogerontology · doi:10.1007/s10522-014-9514-3 · Cited by 104
Conjugate Vaccine Immunotherapy for Substance Use Disorder
Bremer, P. T., & Janda, K. D. (2017) · Pharmacological Reviews · doi:10.1124/pr.117.013904 · Cited by 102
Dynamic vaccine blocks relapse to compulsive intake of heroin
Schlosburg, J. E., Vendruscolo, L. F., Bremer, P. T., Lockner, J. W., Wade, C. L., Nunes, A. A. K., Stowe, G. N., Edwards, S., Janda, K. D., & Koob, G. F. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1219159110 · Cited by 101
Development of a Clinically Viable Heroin Vaccine
Bremer, P. T., Schlosburg, J. E., Banks, M. L., Steele, F. F., Zhou, B., Poklis, J. L., & Janda, K. D. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.7b03334 · Cited by 101
Elion, D. L., & Cook, R. S. (2018) · Oncotarget · doi:10.18632/oncotarget.25626 · Cited by 101
The perfect personalized cancer therapy: cancer vaccines against neoantigens
Aurisicchio, L., Pallocca, M., Ciliberto, G., & Palombo, F. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0751-1 · Cited by 97
Emerging Technologies for Low‐Cost, Rapid Vaccine Manufacture
Kis, Z., Shattock, R. J., Shah, N., & Kontoravdi, C. (2019) · Biotechnology Journal · doi:10.1002/biot.201970055 · Cited by 96
Welter, J., Taylor, J., Tartaglia, J., Paoletti, E., & Stephensen, C. B. (2000) · Journal of Virology · doi:10.1128/jvi.74.14.6358-6367.2000 · Cited by 94
Systemic activation of antigen-presenting cells via RNA-loaded nanoparticles
Sayour, E. J., De Leon, G., Pham, C., Grippin, A., Kemeny, H., Chua, J., Huang, J., Sampson, J. H., Sanchez-Perez, L., Flores, C., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2016.1256527 · Cited by 93
Luther, C., Adamopoulou, E., Stoeckle, C., Brucklacher-Waldert, V., Rosenkranz, D., Stoltze, L., Lauer, S., Poeschel, S., Melms, A., & Tolosa, E. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802046 · Cited by 93
Pravetoni, M., Naour, M. L., Harmon, T. M., Tucker, A. M., Portoghese, P. S., & Pentel, P. R. (2012) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.189506 · Cited by 90
Bialkowski, L., van Weijnen, A., der Jeught, K. V., Renmans, D., Daszkiewicz, L., Heirman, C., Stangé, G. M., Breckpot, K., Aerts, J. L., & Thielemans, K. (2016) · Scientific Reports · doi:10.1038/srep22509 · Cited by 90
López‐Camacho, C., Abbink, P., Larocca, R. A., Dejnirattisai, W., Boyd, M. B., Badamchi-Zadeh, A., Wallace, Z., Doig, J., Sanchez-Velazquez, R., Lins, R. D., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04859-5 · Cited by 88
Easton, A. J., Scott, P. D., Edworthy, N. L., Meng, B., Marriott, A. C., & Dimmock, N. J. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.01.102 · Cited by 87
Influenza Virus Protecting RNA: an Effective Prophylactic and Therapeutic Antiviral
Dimmock, N. J., Rainsford, E. W., Scott, P. D., & Marriott, A. C. (2008) · Journal of Virology · doi:10.1128/jvi.00743-08 · Cited by 87
Immunosenescence: a problem of lymphopoiesis, homeostasis, microenvironment, and signaling
Cambier, J. C. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00276.x · Cited by 84
Granstein, R. D., Ding, W., & Ozawa, H. (2000) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2000.00929.x · Cited by 82
Li, H., Li, Y., Wang, X., Hou, Y., Hong, X., Gong, T., Zhang, Z., & Sun, X. (2017) · Theranostics · doi:10.7150/thno.20745 · Cited by 82
Computational tools for epitope vaccine design and evaluation
He, L., & Zhu, J. (2015) · Current Opinion in Virology · doi:10.1016/j.coviro.2015.03.013 · Cited by 81
Graham, B. S., Mascola, J. R., & Fauci, A. S. (2018) · JAMA · doi:10.1001/jama.2018.0345 · Cited by 81
Impact of Distinct Chemical Structures for the Development of a Methamphetamine Vaccine
Moreno, A. Y., Mayorov, A. V., & Janda, K. D. (2011) · Journal of the American Chemical Society · doi:10.1021/ja108807j · Cited by 80
Selection of a Novel Anti-Nicotine Vaccine: Influence of Antigen Design on Antibody Function in Mice
Pryde, D. C., Jones, L. H., Gervais, D. P., Stead, D. R., Blakemore, D. C., Selby, M. D., Brown, A. D., Coe, J. W., Badland, M., Beal, D. M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076557 · Cited by 80
Virus-Like Particles Induce MHC Class I-Restricted T-Cell Responses
Schirmbeck, R., Böhm, W., & Reimann, J. (1996) · Intervirology · doi:10.1159/000150482 · Cited by 79
Cumberbatch, M., Dearman, R. J., & Kimber, I. (2002) · Immunology · doi:10.1046/j.1365-2567.2002.01381.x · Cited by 78
Varypataki, E. M., Benne, N., Bouwstra, J. A., Jiskoot, W., & OSSENDORP, F. A. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0283 · Cited by 78
An Immunotherapeutic Program for the Treatment of Nicotine Addiction: Hapten Design and Synthesis
Isomura, S., Wirsching, P., & Janda, K. D. (2001) · The Journal of Organic Chemistry · doi:10.1021/jo001442w · Cited by 78
A critical evaluation of a nicotine vaccine within a self-administration behavioral model
Moreno, A. Y., Azar, M. R., Warren, N. A., Dickerson, T. J., Koob, G. F., & Janda, K. D. (2010) · Molecular Pharmaceutics · doi:10.1021/mp900213u · Cited by 73
Tumour virus vaccines: hepatitis B virus and human papillomavirus
Stanley, M. (2017) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2016.0268 · Cited by 73
Latest Development on RNA-Based Drugs and Vaccines
Lundstrom, K. H. (2018) · Future Science OA · doi:10.4155/fsoa-2017-0151 · Cited by 72
Pravetoni, M., Naour, M. L., Tucker, A. M., Harmon, T. M., Hawley, T. M., Portoghese, P. S., & Pentel, P. R. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3013745 · Cited by 71
Jalah, R., Torres, O. B., Mayorov, A. V., Li, F., Antoline, J. F. G., Jacobson, A. E., Rice, K. C., Deschamps, J. R., Beck, Z., Alving, C. R., et al. (2015) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.5b00085 · Cited by 71
Cancer Vaccine Immunotherapy with RNA-Loaded Liposomes
Sayour, E. J., Méndez‐Gómez, H. R., & Mitchell, D. A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19102890 · Cited by 70
Pravetoni, M., Pentel, P. R., Potter, D. N., Chartoff, E. H., Tally, L., & LeSage, M. G. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101807 · Cited by 69
Porkolab, V., Chabrol, E., Varga, N., Ordanini, S., Sutkevičiu̅tė, I., Thépaut, M., García‐Jiménez, M. J., Girard, É., Nieto, P. M., Bernardi, A., et al. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.7b00958 · Cited by 69
Espinosa, D. A., Christensen, D., Muñoz, C. A., Singh, S. P., Locke, E., Andersen, P. L., & Zavala, F. P. (2017) · npj Vaccines · doi:10.1038/s41541-017-0011-y · Cited by 68
Strategies for developing and optimizing cancer vaccines
Maeng, H. M., & Berzofsky, J. A. (2019) · F1000Research · doi:10.12688/f1000research.18693.1 · Cited by 68
Using Hapten Design to Discover Therapeutic Monoclonal Antibodies for Treating Methamphetamine Abuse
Peterson, E. C., Gunnell, M. G., Che, Y., Goforth, R. L., Carroll, F. I., Henry, R. L., Liu, H., & Owens, S. M. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.117150 · Cited by 67
DNA Vaccines: Regulatory Considerations and Safety Aspects
Myhr, A. I. (2016) · Current Issues in Molecular Biology · doi:10.21775/cimb.022.079 · Cited by 67
Wu, N. C., Lv, H., Thompson, A. J., Wu, D. C., Ng, W. W., Kadam, R. U., Lin, C.-W., Nycholat, C. M., McBride, R., Liang, W., et al. (2019) · Cell Host & Microbe · doi:10.1016/j.chom.2019.04.013 · Cited by 67
Sulima, A., Jalah, R., Antoline, J. F. G., Torres, O. B., Imler, G. H., Deschamps, J. R., Beck, Z., Alving, C. R., Jacobson, A. E., Rice, K. C., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01427 · Cited by 66
Toxoid Vaccination against Bacterial Infection Using Cell Membrane-Coated Nanoparticles
Angsantikul, P., Fang, R. H., & Zhang, L. (2017) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.7b00692 · Cited by 65
Jalali, S. A., Sankian, M., Tavakkol‐Afshari, J., & Jaafari, M. R. (2011) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2011.09.010 · Cited by 64
Cited by
The clinical progress of mRNA vaccines and immunotherapies
Barbier, A. J., Jiang, A. Y., Zhang, P., Wooster, R., & Anderson, D. G. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01294-2 · Cited by 823
Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19
Ward, B. J., Gobeil, P., Séguin, A., Atkins, J., Boulay, I., Charbonneau, P.-Y., Couture, M., D’Aoust, M.-A., Dhaliwall, J., Finkle, C., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01370-1 · Cited by 360
DNA vaccines against COVID-19: Perspectives and challenges
Silveira, M. M., Moreira, G. M. S. G., & Mendonça, M. (2021) · Life Sciences · doi:10.1016/j.lfs.2020.118919 · Cited by 285
Evolution of Cancer Vaccines—Challenges, Achievements, and Future Directions
Tay, B. Q., Wright, Q., Ladwa, R., Perry, C., Leggatt, G., Simpson, F., Wells, J. W., Panizza, B. J., Frazer, I. H., & Cruz, J. L. G. (2021) · Vaccines · doi:10.3390/vaccines9050535 · Cited by 76
Rahman, A., Islam, M. J., Karim, M. R., Kundu, D., & Kabir, S. (2021) · 2021 International Conference on Electronics, Communications and Information Technology (ICECIT) · doi:10.1109/icecit54077.2021.9641303 · Cited by 21
Metadata
- Authors
- Brisse, M., Vrba, S. M., Kirk, N., Liang, Y., & Ly, H.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2020-09-30
- Volume
- 11
- Pages
- 583077-583077
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W3089805074
- Cited by
- 323
- References
- 260
- FWCI
- 11.56
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.